What is Cbd Life Sciences Inc?
engages in the development and marketing a line of cannabidiol based organic products.
CBDL · Verdict
Limited reward · elevated risk
CBDL's standout is balance sheet; volatility and cash flow weigh on the picture.
Based on 88% data coverage
CBDL · Verdict
Current ratio 15.12
Weak vs peers
-142% free-cash-flow margin
Rev -15.0% CAGR · earnings -61.5%
-50% net margin · -45% ROE
Model-based scoring. For information only — not financial advice.
engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, coffee, wine, skincare line, tablets, and a line of pet products. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 2.37M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.